Previous evidence has suggested that CD36+ CML LSCs mediate chemoresistance via increased fatty acid oxidation, and home to adipose tissue niches within the BM [63]. The gene discussed is CD36; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.